tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Grenier FC et al. A whole blood FK 506 assay for the IMx analyzer. 1991 Transplant. Proc. pmid:1721264
Friob MC et al. A combined HPLC-ELISA evaluation of FK 506 in transplant patients. 1991 Transplant. Proc. pmid:1721265
Bierer BE et al. FK 506 and rapamycin: molecular probes of T-lymphocyte activation. 1991 Transplant. Proc. pmid:1721296
Tanida I et al. Yeast cyclophilin-related gene encodes a nonessential second peptidyl-prolyl cis-trans isomerase associated with the secretory pathway. 1991 Transplant. Proc. pmid:1721297
Hultsch T and Hohman RJ Categorizing receptor-signaling pathways with FK 506 and rapamycin. 1991 Transplant. Proc. pmid:1721328
Takai K et al. Immunosuppressive effects of FK 506 on rat lymphoid organs. 1991 Transplant. Proc. pmid:1721329
Carroll PB et al. Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. 1991 Transplantation pmid:1702911
Starzl TE et al. Hepatotrophic effects of FK506 in dogs. 1991 Transplantation pmid:1702912
Dew MA et al. Quality-of-life advantages of FK 506 vs conventional immunosuppressive drug therapy in cardiac transplantation. 1991 Transplant. Proc. pmid:1721360
Shapiro R et al. FK 506 in clinical kidney transplantation. 1991 Transplant. Proc. pmid:1721361
Rilo HL et al. Effect of FK 506 on function of human islets of Langerhans. 1991 Transplant. Proc. pmid:1721393
Carroll PB et al. Synexin: a target protein for toxic effects of cyclosporine and FK 506 in endocrine cells. 1991 Transplant. Proc. pmid:1721394
Sewing KF and Christians U FK 506. 1991 Lancet pmid:1704090
Wiederrecht G et al. FKB1 encodes a nonessential FK 506-binding protein in Saccharomyces cerevisiae and contains regions suggesting homology to the cyclophilins. 1991 Proc. Natl. Acad. Sci. U.S.A. pmid:1704127
Santiago SF et al. Effect of donor pretreatment with FK 506 upon small intestine allotransplantation in rats. 1991 Transplant. Proc. pmid:1721423
Murase N et al. Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. 1991 Transplant. Proc. pmid:1721424
Palaszynski EW et al. Purification and characterization of cyclosporine and FK-506 binding proteins from a human T-helper cell line. 1991 Clin. Biochem. pmid:1711940
Shiraki K et al. Effect of FK-506 on replication of human cytomegalovirus in vitro. 1991 J. Antibiot. pmid:1712008
Liversidge J et al. FK 506 modulates accessory cell adhesion molecule expression and inhibits CD4 lymphocyte adhesion to retinal pigment epithelial cells in vitro: implications for therapy of uveoretinitis. 1991 Transplant. Proc. pmid:1721455
Mochizuki M et al. A multicenter clinical open trial of FK 506 in refractory uveitis, including Behçet's disease. Japanese FK 506 Study Group on Refractory Uveitis. 1991 Transplant. Proc. pmid:1721456
FK 506--an investigational immunosuppressant. 1991 Med Lett Drugs Ther pmid:1716722
Ricordi C et al. In vivo effect of FK506 on human pancreatic islets. 1991 Transplantation pmid:1716797
Katz IA et al. Comparison of the effects of FK506 and cyclosporine on bone mineral metabolism in the rat. A pilot study. 1991 Transplantation pmid:1716801
Morris RE Rapamycin: FK506's fraternal twin or distant cousin? 1991 Immunol. Today pmid:1715165
Baumann G et al. Cyclosporin A and FK-506 both affect DNA binding of regulatory nuclear proteins to the human interleukin-2 promoter. 1991 New Biol. pmid:1715185
Sakr MF et al. Protective effect of FK 506 against hepatic ischemia in rats. 1991 Transplant. Proc. pmid:1703689
Katayama Y et al. Immunosuppressive effects of FK 506 and 15-deoxyspergualin in rat lung transplantation. 1991 Transplant. Proc. pmid:1703690
Jordan ML et al. Initial studies with FK506 in renal transplantation. 1991 Sep-Oct Cleve Clin J Med pmid:1718631
Andersson J et al. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. 1992 Immunology pmid:1371491
Strasser S et al. Effect of FK506 on insulin secretion in normal dogs. 1992 Metab. Clin. Exp. pmid:1371575
Andersson J et al. FK 506 and cyclosporine inhibit antigen- or mitogen-induced monokine and lymphokine production in vitro. 1992 Transplant. Proc. pmid:1371621
Matsuura T et al. Blockade of interleukin-2 production from cloned T cells by cyclosporine and FK 506 assessed by proliferation assays in vitro. 1992 Transplant. Proc. pmid:1371623
Moutabarrik A et al. In vitro FK506 kidney tubular cell toxicity. 1992 Transpl. Int. pmid:14621743
Okamura N et al. Enhanced liver regeneration by FK 506 can be blocked by interleukin-1 alpha and interleukin-2. 1992 Transplant. Proc. pmid:1371624
Moutabarrik A et al. FK506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells. 1992 Transpl. Int. pmid:14621744
Sakr M et al. Effect of renal ischemia on plasma levels of FK 506 in rats. 1992 Transplant. Proc. pmid:1371625
Stangl MJ et al. The use of FK506 and RS61443 for reversal of small-bowel rejection. 1992 Transpl. Int. pmid:14621800
Kusne S et al. Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation. 1992 Transplant. Proc. pmid:1371626
Wijnen RM et al. Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. 1992 Transpl. Int. pmid:14621844
Lee C et al. FK-506 binding protein from Tolypocladium inflatum: resistance of FKBP/FK-506 complex against proteolysis. 1992 Biochem. Biophys. Res. Commun. pmid:1371677
Jiang H et al. Control of humoral and cellular immunity-mediated accelerated heart allograft rejection in sensitized rats by low dose FK 506 and splenectomy. 1992 Transpl. Int. pmid:14621859
Edkins RD et al. Comparison of cyclosporine and FK506 effects on glutathione levels in rat cochlea, brain, liver and kidney. 1992 Biochem. Pharmacol. pmid:1371687
Kobayashi N et al. Abdominal organ cluster transplantation in pigs and FK506. 1992 Transpl. Int. pmid:14621861
Galat A et al. A rapamycin-selective 25-kDa immunophilin. 1992 Biochemistry pmid:1371698
Hung DT and Schreiber SL cDNA cloning of a human 25 kDa FK506 and rapamycin binding protein. 1992 Biochem. Biophys. Res. Commun. pmid:1374240
Jayaraman T et al. FK506 binding protein associated with the calcium release channel (ryanodine receptor). 1992 J. Biol. Chem. pmid:1374404
Höllsberg P et al. Characterization of HTLV-I in vivo infected T cell clones. IL-2-independent growth of nontransformed T cells. 1992 J. Immunol. pmid:1374452
Schreiber SL and Crabtree GR The mechanism of action of cyclosporin A and FK506. 1992 Immunol. Today pmid:1374612
Demetris AJ et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. 1992 Transplantation pmid:1374944
Bundick RV et al. FK506 as an agonist to induce inhibition of interleukin 2 production. 1992 Transplantation pmid:1374947
Sakr M et al. The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats. 1992 Transplantation pmid:1374948
Lepre CA et al. Solution structure of FK506 bound to FKBP-12. 1992 FEBS Lett. pmid:1375171
Ruff VA et al. FKBP-12 is not an inhibitor of protein kinase C. 1992 Immunol. Invest. pmid:1375189
Date K et al. Effect of FK 506 on graft survival in rat small intestinal allografts. 1992 Transplant. Proc. pmid:1376516
Hatazawa C et al. Effect of FK 506 on bowel transplantation in rats. 1992 Transplant. Proc. pmid:1376517
Jain A et al. Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients. 1992 Transplant. Proc. pmid:1376518
Masutani H et al. Suppression of the histologic changes of GVHD by FK 506 in rat small bowel transplantation. 1992 Transplant. Proc. pmid:1376519
Santiago SF et al. Effect of short-term immunosuppressive therapy with FK 506 or CyA on the donor in small intestine allotransplantation in rats. 1992 Transplant. Proc. pmid:1376520
Utsunomiya H et al. Effect of FK 506 on orthotopic small bowel transplantation in rats. 1992 Transplant. Proc. pmid:1376521
Yagihashi A et al. Changes in cell surface markers in human small bowel transplantation with FK 506. 1992 Transplant. Proc. pmid:1376522
Abu-Elmagd K et al. Management of intestinal transplantation in humans. 1992 Transplant. Proc. pmid:1376523
Takaori K et al. Basic study on immunologic effects of cyclosporine and FK 506 for application to pancreatic transplantation. 1992 Transplant. Proc. pmid:1376531
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation using the cuff technique in rats. 1992 Transplant. Proc. pmid:1376532
Yagihashi A et al. HLA matching effect in liver transplantation. 1992 Transplant. Proc. pmid:1281569
Kobayashi M et al. Posttransplant donor-specific T-lymphocytotoxic antibody in liver transplant patients with a positive crossmatch. 1992 Transplant. Proc. pmid:1281570
Lemster B et al. Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid, or brequinar sodium. 1992 Transplant. Proc. pmid:1281576
Tze WJ et al. FK 506: an effective immunosuppressant for islet xenotransplantation. 1992 Transplant. Proc. pmid:1281577
Kamei T et al. Established intraportal islet allograft is rejected despite the acceptance of donor-specific second cardiac allograft. 1992 Transplant. Proc. pmid:1281579
Woo J et al. FK 506 treatment following syngeneic bone marrow transplantation does not inhibit clonal deletion of V beta 5+ or V beta 11+ T cells. 1992 Transplant. Proc. pmid:1281583
Souza ER et al. Acute effects of FK 506 on glomerular hemodynamics. 1992 Transplant. Proc. pmid:1281585
Hanke JH et al. FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA. 1992 Lymphokine Cytokine Res. pmid:1281674
Logan TM et al. Side chain and backbone assignments in isotopically labeled proteins from two heteronuclear triple resonance experiments. 1992 FEBS Lett. pmid:1281793
Bergstrand H et al. Modulation of neutrophil superoxide generation by inhibitors of protein kinase C, calmodulin, diacylglycerol and myosin light chain kinases, and peptidyl prolyl cis-trans isomerase. 1992 J. Pharmacol. Exp. Ther. pmid:1281879
Thomson AW The spectrum of action of new immunosuppressive drugs. 1992 Clin. Exp. Immunol. pmid:1379130
Fischer G et al. Mip protein of Legionella pneumophila exhibits peptidyl-prolyl-cis/trans isomerase (PPlase) activity. 1992 Mol. Microbiol. pmid:1379319
Rondeau E [Mechanism of action of the new immunosuppressants: cyclosporin A, FK 506 and rapamycin]. 1992 Nephrologie pmid:1379348
Schreiber SL Immunophilin-sensitive protein phosphatase action in cell signaling pathways. 1992 Cell pmid:1379518
Aldape RA et al. Charged surface residues of FKBP12 participate in formation of the FKBP12-FK506-calcineurin complex. 1992 J. Biol. Chem. pmid:1379588
Langrehr JM et al. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. 1992 J. Clin. Invest. pmid:1379617
Kumano K et al. [Functional and morphological changes in rat kidney induced by FK506 and its reversal by various vasodilators]. 1992 Nippon Hinyokika Gakkai Zasshi pmid:1379657
Woodle ES et al. FK506: inhibition of humoral mechanisms of hepatic allograft rejection. 1992 Transplantation pmid:1379749
Sato K et al. Effectiveness of triple drug immunosuppression for pancreaticoduodenal allotransplantation in dogs. 1992 Transplant. Proc. pmid:1379753
Baumann G et al. Molecular mechanisms of immunosuppression. 1992 J. Autoimmun. pmid:1380246
Walpoth B et al. Assessment of new immunosuppressive drugs in a rat cardiac allograft heterotopic model. 1992 Eur Surg Res pmid:1380460
Petros AM et al. Conformation of two non-immunosuppressive FK506 analogs when bound to FKBP by isotope-filtered NMR. 1992 FEBS Lett. pmid:1380470
Van Thiel DH et al. FK 506 reduces the injury experienced following renal ischemia and reperfusion. 1992 Ren Fail pmid:1380720
Bolton C The efficacy of cyclosporin A, FK-506 and prednisolone to modify the adoptive transfer of experimental allergic encephalomyelitis (EAE). 1992 Agents Actions pmid:1380765
Terada N et al. Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells. 1992 Biochem. Biophys. Res. Commun. pmid:1380801
Friccius H et al. The effects of the antifungal azoles itraconazole, fluconazole, ketoconazole and miconazole on cytokine gene expression in human lymphoid cells. 1992 Int. J. Immunopharmacol. pmid:1380951
Dumont FJ et al. The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. 1992 J. Exp. Med. pmid:1380976
Norris AA et al. Protective effects of cyclophosphamide, cyclosporin A and FK506 against antigen-induced lung eosinophilia in guinea-pigs. 1992 Clin. Exp. Immunol. pmid:1381297
Meiser BM et al. Continuous infusion of angiopeptin significantly reduces accelerated graft vessel disease induced by FK 506 in a rat heart allograft model. 1992 Transplant. Proc. pmid:1384201
Wakabayashi H et al. Effect of FK 506 and cyclosporine A on hepatic energy status in the rat after warm ischemia, as monitored by 31P nuclear magnetic resonance spectroscopy in vivo. 1992 Transplant. Proc. pmid:1384205
Griffin AD et al. FK 506 in canine renal transplantation. 1992 Transplant. Proc. pmid:1384209
Griffiths RJ et al. Characterisation of passively transferred antigen arthritis induced by methylated bovine serum albumin in the rat: effect of FK 506 on arthritis development. 1992 Agents Actions pmid:1384284
Todo S et al. Intestinal transplantation in composite visceral grafts or alone. 1992 Ann. Surg. pmid:1384443
Massol N et al. Rabbit FKBP59-heat shock protein binding immunophillin (HBI) is a calmodulin binding protein. 1992 Biochem. Biophys. Res. Commun. pmid:1384470
Siekierka JJ and Sigal NH FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond. 1992 Curr. Opin. Immunol. pmid:1384551
Hultsch T et al. The effect of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines. 1992 Mol. Biol. Cell pmid:1384815
Petros AM et al. Identification of solvent-exposed regions of an FK-506 analog, ascomycin, bound to FKBP using a paramagnetic probe. 1992 J. Biomol. NMR pmid:1384850